and β-Lactams: Emerging Insights and Potential Opportunities

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2018 Oct 16

PMID 30319581

Citations 29

Authors

Elizabeth Story-Roller

Emily C Maggioncalda

Keira A Cohen

Gyanu Lamichhane

Affiliations

Soon will be listed here.

Abstract

β-lactams, the most widely used class of antibiotics, are well-tolerated, and their molecular mechanisms of action against many bacteria are well-documented. () is a highly drug-resistant rapidly-growing nontuberculous mycobacteria (NTM). Only in recent years have we started to gain insight into the unique relationship between β-lactams and their targets in . In this mini-review, we summarize recent findings that have begun to unravel the molecular basis for overall efficacy of β-lactams against and discuss emerging evidence that indicates that we have yet to harness the full potential of this antibiotic class to treat infections.

Citing Articles

Deep learning-based prediction of chemical accumulation in a pathogenic mycobacterium.

Sullivan M, Rubin E bioRxiv. 2025; .

PMID: 39764009 PMC: 11702553. DOI: 10.1101/2024.12.15.628588.

Durlobactam in combination with β-lactams to combat .

Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D Antimicrob Agents Chemother. 2024; 69(2):e0117424.

PMID: 39714147 PMC: 11823594. DOI: 10.1128/aac.01174-24.

Analysis of Clinical Isolation Characteristics of Nontuberculous Mycobacteria and Drug Sensitivity of Rapidly Growing Mycobacteria in the General Hospital of Guangzhou, China.

Liu X, Lin Z, Li Y, Zhong Z, Wu A, Jiang Y Infect Drug Resist. 2024; 17:4079-4088.

PMID: 39319037 PMC: 11420897. DOI: 10.2147/IDR.S465468.

Assessment of the Efficacy of the Antihistamine Drug Rupatadine Used Alone or in Combination against Mycobacteria.

Tian X, Ma W, Yusuf B, Su B, Hu J, Zhang T Pharmaceutics. 2024; 16(8).

PMID: 39204394 PMC: 11359651. DOI: 10.3390/pharmaceutics16081049.

Orphan response regulator NnaR is critical for nitrate and nitrite assimilation in .

Simcox B, Rohde K Front Cell Infect Microbiol. 2024; 14:1411333.

PMID: 38854658 PMC: 11162112. DOI: 10.3389/fcimb.2024.1411333.

References

Ito K, Hashimoto K, Ogata H . [Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus]. Kekkaku. 2003; 78(9):587-90. View

Wang F, Cassidy C, Sacchettini J . Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob Agents Chemother. 2006; 50(8):2762-71. PMC: 1538687. DOI: 10.1128/AAC.00320-06. View

Brown-Elliott B, Killingley J, Vasireddy S, Bridge L, Wallace Jr R . In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest. J Clin Microbiol. 2016; 54(6):1586-1592. PMC: 4879266. DOI: 10.1128/JCM.00298-16. View

Lavollay M, Dubee V, Heym B, Herrmann J, Gaillard J, Gutmann L . In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect. 2013; 20(5):O297-300. DOI: 10.1111/1469-0691.12405. View

Park S, Kim S, Park E, Kim H, Kwon O, Chang C . In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci. 2008; 23(1):49-52. PMC: 2526484. DOI: 10.3346/jkms.2008.23.1.49. View

Sfeir M, Walsh M, Rosa R, Aragon L, Liu S, Cleary T . Complex Infections: A Retrospective Cohort Study. Open Forum Infect Dis. 2018; 5(2):ofy022. PMC: 5808791. DOI: 10.1093/ofid/ofy022. View

Viana-Niero C, Lima K, Lopes M, da Silva Rabello M, Marsola L, Brilhante V . Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol. 2008; 46(3):850-5. PMC: 2268380. DOI: 10.1128/JCM.02052-07. View

Mougari F, Amarsy R, Veziris N, Bastian S, Brossier F, Bercot B . Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother. 2016; 71(8):2208-12. DOI: 10.1093/jac/dkw130. View

Pavelka Jr M, Mahapatra S, Crick D . Genetics of Peptidoglycan Biosynthesis. Microbiol Spectr. 2015; 2(4):MGM2-0034-2013. DOI: 10.1128/microbiolspec.MGM2-0034-2013. View

10.

Park J, Strominger J . Mode of action of penicillin. Science. 1957; 125(3238):99-101. DOI: 10.1126/science.125.3238.99. View

11.

Pryjma M, Burian J, Thompson C . Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105836. DOI: 10.1128/AAC.00283-18. View

12.

Koh W, Jeon K, Lee N, Kim B, Kook Y, Lee S . Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2010; 183(3):405-10. DOI: 10.1164/rccm.201003-0395OC. View

13.

Jeon K, Kwon O, Lee N, Kim B, Kook Y, Lee S . Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009; 180(9):896-902. DOI: 10.1164/rccm.200905-0704OC. View

14.

Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T . Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012; 50(11):3556-61. PMC: 3486228. DOI: 10.1128/JCM.01175-12. View

15.

Soroka D, Dubee V, Soulier-Escrihuela O, Cuinet G, Hugonnet J, Gutmann L . Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. J Antimicrob Chemother. 2013; 69(3):691-6. DOI: 10.1093/jac/dkt410. View

16.

Lee M, Sun P, Wu T, Wang L, Yang C, Chung W . Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. J Antimicrob Chemother. 2017; 72(10):2782-2786. DOI: 10.1093/jac/dkx212. View

17.

Nash K, Brown-Elliott B, Wallace Jr R . A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009; 53(4):1367-76. PMC: 2663066. DOI: 10.1128/AAC.01275-08. View

18.

Candido P, de Souza Nunes L, Marques E, Folescu T, Coelho F, Calado Nogueira de Moura V . Multidrug-resistant nontuberculous mycobacteria isolated from cystic fibrosis patients. J Clin Microbiol. 2014; 52(8):2990-7. PMC: 4136125. DOI: 10.1128/JCM.00549-14. View

19.

Chihara S, Smith G, Petti C . Carbapenem susceptibility patterns for clinical isolates of Mycobacterium abscessus determined by the Etest method. J Clin Microbiol. 2009; 48(2):579-80. PMC: 2815599. DOI: 10.1128/JCM.01930-09. View

20.

Shen G, Wu B, Hu S, Lin C, Wu K, Chen J . High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents. 2010; 35(4):400-4. DOI: 10.1016/j.ijantimicag.2009.12.008. View